计算溶液所需的质量、体积或浓度。
Information
Imigran
Succinate (GR 43175) is a triptan sulfa drug containing a sulfonamide group for the treatment of migraine headaches.
In vitro
Imigran
displays the highest affinity for 5-HT1D (Ki = 17 nM) and 5-HT1B (Ki = 27 nM) binding sites and is slightly less potent at 5-HT1A binding sites (Ki = 100 nM).
Imigran
markedly attenuates plasma protein extravasation induced by electrical trigeminal ganglion stimulation.
Imigran
reduces morphological changes in post-capillary venules and mast cells within dura mater following electrical trigeminal ganglion stimulation.
In vivo
Imigran
at a clinically relevant dose (100 mg/kg, s.c.) leads to a significant reduction of the mechanical allodynia-like behaviour on both the injured and the contralateral sides (peak-effects 6.3 g and 4.4 g, respectively) in a rat model of trigeminal neuropathic pain.
Imigran
reduces the numbers of Fos-positive cells found in laminae I and IIo of the trigeminal nucleus caudalis and C2 (6, 13 cells and 9 cells, respectively) after mechanical stimulation in cats.
Imigran
constricts selectively the cranial vessels that are distended and inflamed during migraine, the action is mediated by activation of a 5-HT1 receptor subtype which has been shown in animals to be localized in cranial vessels.
Imigran
results in oral bioavailabilities of 37, 58 and 23% in rat, dog and rabbit, respectively.
Imigran
is cleared rapidly by metabolic and renal clearance with a half-life of 1-2 hour in rat, dog and rabbit.
Imigran
produces few adverse pharmacodynamic effects when administered acutely, except at high doses, although it is less well tolerated in dogs.
Cell Data
cell lines:Human colon cancer HCA-7 cell lines
Concentrations:
Incubation Time:
Powder Purity:≥99%
H318: 造成严重的眼睛损伤